Apretero 125/80 Kit [Aprepitant (125mg) + Aprepitant (80mg)] – 1 kit

About this Medicine

Apretero 125/80 Kit is a specialized prescription medication designed to significantly reduce the challenging symptoms of nausea and vomiting often experienced by patients undergoing chemotherapy. Known medically as chemotherapy-induced nausea and vomiting (CINV), these side effects can be debilitating, impacting a patient's quality of life and potentially interfering with their treatment schedule. Apretero, containing the active ingredient aprepitant, works by selectively blocking a substance in the brain called substance P, which is involved in transmitting nausea and vomiting signals. Specifically, aprepitant is an NK1 (neurokinin 1) receptor antagonist, targeting these receptors to disrupt the pathway that triggers emesis. The Apretero 125/80 Kit is formulated as a convenient three-day regimen to provide sustained protection. The kit typically includes a 125mg capsule for administration on Day 1, followed by 80mg capsules for Days 2 and 3. This structured dosing schedule is crucial for achieving optimal antiemetic coverage, particularly during the acute and delayed phases of CINV. By effectively managing these symptoms, Apretero helps patients maintain their nutritional intake, participate more actively in their daily lives, and adhere more consistently to their critical chemotherapy treatments. Preventing CINV is not just about comfort; it's an essential component of comprehensive cancer care. Uncontrolled nausea and vomiting can lead to dehydration, malnutrition, and a decrease in overall well-being, potentially requiring hospitalizations or delays in life-saving therapies. Apretero offers a targeted approach to mitigate these severe side effects, allowing patients to focus their energy on recovery and treatment rather than enduring profound discomfort. Always consult your healthcare provider to determine if Apretero is suitable for your specific chemotherapy regimen and to understand how it integrates into your overall care plan.